BackDiamond Biotechnology , Ltd Overview

Diamond Biotechnology , Ltd Receivables

Diamond Biotechnology , Ltd's receivables is $120M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$118.44M
↓ 39.25% YoYΔ $-76.51M vs prior year quarter

Peer trimmed avg / median

Loading

Diamond Biotechnology , Ltd Receivables History

Loading

Diamond Biotechnology , Ltd vs. peers: Receivables Comparison

Loading

Diamond Biotechnology , Ltd Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Diamond Biotechnology , Ltd (6815.TWO) FAQ

As of the most recent data (June 2026), 6815.TWO shows a receivables of $120M. That compares with $190M in the prior-year period — down 39.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6815.TWO's receivables is now $120M (was $190M) — a 39.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Diamond Biotechnology , Ltd is outperforming or lagging.

Tracking 6815.TWO's receivables over time shows whether Diamond Biotechnology , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $190M in the prior-year period — down 39.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Diamond Biotechnology , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $120M) with ownership activity and broader fundamentals.